Serena Lavorgna

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

The role of Bladder EpiCheck® test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study.

The role of Bladder EpiCheck® test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study.

Journal: Urologia
Published: April 17, 2026

Evidence-based framework for organisational best practice recommendations in healthcare governance.

Evidence-based framework for organisational best practice recommendations in healthcare governance.

Journal: Frontiers in health services
Published: February 03, 2026

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial.

Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial.

Journal: Haematologica
Published: August 11, 2021

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol.

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol.

Journal: Blood advances
Published: July 08, 2021

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation.

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation.

Journal: Cancers
Published: January 10, 2021

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.

Journal: Blood advances
Published: July 29, 2020

Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells.

Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells.

Journal: Blood cancer journal
Published: July 02, 2020

Corrigendum to "STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype" [Leuk. Res. 78 (2019) 21-23].

Corrigendum to "STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype" [Leuk. Res. 78 (2019) 21-23].

Journal: Leukemia research
Published: May 09, 2020

When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia.

When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia.

Journal: Chemotherapy
Published: March 30, 2020

WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine.

WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine.

Journal: Leukemia & lymphoma
Published: December 05, 2019

Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.

Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse.

Journal: American journal of hematology
Published: July 02, 2019

Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML.

Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD+ AML.

Journal: Blood advances
Published: June 03, 2019
Showing 1-12 of 35

Last Updated: 09/26/2026